US 2026/0285987 A1Published application

Monospecific anti-frizzled antibodies and methods of use

AssigneeSurrozen Operating, Inc.

InventorsYang LI, Thomas Steven LOPEZ, I-Chieh WANG, Parthasarathy SAMPATHKUMAR

Life of this patent

Estimating the term…

Abstract

The present invention provides anti-Fzd monoclonal antibodies and related compositions, which may be used in any of a variety of therapeutic methods for the treatment of diseases.

Claims18

Dependent claims

An isolated antibody, or an antigen-binding fragment thereof, that binds to a Frizzled 2 (FZD2) receptor, comprising CDR sequences comprising:

(i) CDRH1 of SEQ ID NO:
75;
CDRH2 of SEQ ID NO:
771;
CDRH3 of SEQ ID NO:
1467;
CDRL1 of SEQ ID NO:
2163;
CDRL2 of SEQ ID NO:
2857;
and CDRL3 of SEQ ID NO:
3551;
or
(ii) CDRH1 of SEQ ID NO:
76;
CDRH2 of SEQ ID NO:
772;
CDRH3 of SEQ ID NO:
1468;
CDRL1 of SEQ ID NO:
2164;
CDRL2 of SEQ ID NO:
2858;
and CDRL3 of SEQ ID NO:
3552;
or
(iii) CDRH1 of SEQ ID NO:
77;
CDRH2 of SEQ ID NO:
773;
CDRH3 of SEQ ID NO:
1469;
CDRL1 of SEQ ID NO:
2165;
CDRL2 of SEQ ID NO:
2859;
and CDRL3 of SEQ ID NO:
3553;
or
(iv) CDRH1 of SEQ ID NO:
78;
CDRH2 of SEQ ID NO:
774;
CDRH3 of SEQ ID NO:
1470;
CDRL1 of SEQ ID NO:
2166;
CDRL2 of SEQ ID NO:
2860;
and CDRL3 of SEQ ID NO:
3554;
or
(v) CDRH1 of SEQ ID NO:
79;
CDRH2 of SEQ ID NO:
775;
CDRH3 of SEQ ID NO:
1471;
CDRL1 of SEQ ID NO:
2167;
CDRL2 of SEQ ID NO:
2861;
and CDRL3 of SEQ ID NO:
3555;
or
(vi) CDRH1 of SEQ ID NO:
80;
CDRH2 of SEQ ID NO:
776;
CDRH3 of SEQ ID NO:
1472;
CDRL1 of SEQ ID NO:
2168;
CDRL2 of SEQ ID NO:
2862;
and CDRL3 of SEQ ID NO:
3556;
or
(vii) CDRH1 of SEQ ID NO:
81;
CDRH2 of SEQ ID NO:
777;
CDRH3 of SEQ ID NO:
1473;
CDRL1 of SEQ ID NO:
2169;
CDRL2 of SEQ ID NO:
2863;
and CDRL3 of SEQ ID NO:
3557;
or
(viii) CDRH1 of SEQ ID NO:
82;
CDRH2 of SEQ ID NO:
778;
CDRH3 of SEQ ID NO:
1474;
CDRL1 of SEQ ID NO:
2170;
CDRL2 of SEQ ID NO:
2864;
and CDRL3 of SEQ ID NO:
3558;
or
(ix) CDRH1 of SEQ ID NO:
83;
CDRH2 of SEQ ID NO:
779;
CDRH3 of SEQ ID NO:
1475;
CDRL1 of SEQ ID NO:
2171;
CDRL2 of SEQ ID NO:
2865;
and CDRL3 of SEQ ID NO:
3559;
or
(x) CDRH1 of SEQ ID NO:
84;
CDRH2 of SEQ ID NO:
780;
CDRH3 of SEQ ID NO:
1476;
CDRL1 of SEQ ID NO:
2172;
CDRL2 of SEQ ID NO:
2866;
and CDRL3 of SEQ ID NO:
3560;
or
(xi) CDRH1 of SEQ ID NO:
85;
CDRH2 of SEQ ID NO:
781;
CDRH3 of SEQ ID NO:
1477;
CDRL1 of SEQ ID NO:
2173;
CDRL2 of SEQ ID NO:
2867;
and CDRL3 of SEQ ID NO:
3561;
or
(xii) CDRH1 of SEQ ID NO:
86;
CDRH2 of SEQ ID NO:
782;
CDRH3 of SEQ ID NO:
1478;
CDRL1 of SEQ ID NO:
2174;
CDRL2 of SEQ ID NO:
2868;
and CDRL3 of SEQ ID NO:
3562;
or
(xiii) CDRH1 of SEQ ID NO:
87;
CDRH2 of SEQ ID NO:
783;
CDRH3 of SEQ ID NO:
1479;
CDRL1 of SEQ ID NO:
2175;
CDRL2 of SEQ ID NO:
2869;
and CDRL3 of SEQ ID NO:
3563;
or
(xiv) CDRH1 of SEQ ID NO:
88;
CDRH2 of SEQ ID NO:
784;
CDRH3 of SEQ ID NO:
1480;
CDRL1 of SEQ ID NO:
2176;
CDRL2 of SEQ ID NO:
2870;
and CDRL3 of SEQ ID NO:
3564;
or
(xv) CDRH1 of SEQ ID NO:
89;
CDRH2 of SEQ ID NO:
785;
CDRH3 of SEQ ID NO:
1481;
CDRL1 of SEQ ID NO:
2177;
CDRL2 of SEQ ID NO:
2871;
and CDRL3 of SEQ ID NO:
3565;
or
(xvi) CDRH1 of SEQ ID NO:
90;
CDRH2 of SEQ ID NO:
786;
CDRH3 of SEQ ID NO:
1482;
CDRL1 of SEQ ID NO:
2178;
CDRL2 of SEQ ID NO:
2872;
and CDRL3 of SEQ ID NO:
3566;
or
(xvii) CDRH1 of SEQ ID NO:
91;
CDRH2 of SEQ ID NO:
787;
CDRH3 of SEQ ID NO:
1483;
CDRL1 of SEQ ID NO:
2179;
CDRL2 of SEQ ID NO:
2873;
and CDRL3 of SEQ ID NO:
3567;
or
(xviii) CDRH1 of SEQ ID NO:
92;
CDRH2 of SEQ ID NO:
788;
CDRH3 of SEQ ID NO:
1484;
CDRL1 of SEQ ID NO:
2180;
CDRL2 of SEQ ID NO:
2874;
and CDRL3 of SEQ ID NO:
3568;
or
(xix) CDRH1 of SEQ ID NO:
94;
CDRH2 of SEQ ID NO:
790;
CDRH3 of SEQ ID NO:
1486;
CDRL1 of SEQ ID NO:
2181;
CDRL2 of SEQ ID NO:
2875;
CDRL3 of SEQ ID NO:
3569;
or
(xx) CDRH1 of SEQ ID NO:
95;
CDRH2 of SEQ ID NO:
791;
CDRH3 of SEQ ID NO:
1487;
CDRL1 of SEQ ID NO:
2182;
CDRL2 of SEQ ID NO:
2876;
and CDRL3 of SEQ ID NO:
3570;
or
(xxi) CDRH1 of SEQ ID NO:
97;
CDRH2 of SEQ ID NO:
793;
CDRH3 of SEQ ID NO:
1489;
CDRL1 of SEQ ID NO:
2184;
CDRL2 of SEQ ID NO:
2878;
and CDRL3 of SEQ ID NO:
3572;
or
(xxii) CDRH1 of SEQ ID NO:
98;
CDRH2 of SEQ ID NO:
794;
CDRH3 of SEQ ID NO:
1490;
CDRL1 of SEQ ID NO:
2185;
CDRL2 of SEQ ID NO:
2879;
and CDRL3 of SEQ ID NO:
3573;
or
(xxiii) CDRH1 of SEQ ID NO:
99;
CDRH2 of SEQ ID NO:
795;
CDRH3 of SEQ ID NO:
1491;
CDRL1 of SEQ ID NO:
2186;
CDRL2 of SEQ ID NO:
2880;
and CDRL3 of SEQ ID NO:
3574;
or
(xxiv) CDRH1 of SEQ ID NO:
100;
CDRH2 of SEQ ID NO:
796;
CDRH3 of SEQ ID NO:
1492;
CDRL1 of SEQ ID NO:
2187;
CDRL2 of SEQ ID NO:
2881;
and CDRL3 of SEQ ID NO:
3575;
or
(xxv) CDRH1 of SEQ ID NO:
101;
CDRH2 of SEQ ID NO:
797;
CDRH3 of SEQ ID NO:
1493;
CDRL1 of SEQ ID NO:
2188;
CDRL2 of SEQ ID NO:
2882;
and CDRL3 of SEQ ID NO:
3576;
or
(xxvi) CDRH1 of SEQ ID NO:
103;
CDRH2 of SEQ ID NO:
799;
CDRH3 of SEQ ID NO:
1495;
CDRL1 of SEQ ID NO:
2189;
CDRL2 of SEQ ID NO:
2883;
and CDRL3 of SEQ ID NO:
3577;
or
(xxvii) CDRH1 of SEQ ID NO:
104;
CDRH2 of SEQ ID NO:
800;
CDRH3 of SEQ ID NO:
1496;
CDRL1 of SEQ ID NO:
2190;
CDRL2 of SEQ ID NO:
2884;
and CDRL3 of SEQ ID NO:
3578;
or
(xxviii) CDRH1 of SEQ ID NO:
105;
CDRH2 of SEQ ID NO:
801;
CDRH3 of SEQ ID NO:
1497;
CDRL1 of SEQ ID NO:
2191;
CDRL2 of SEQ ID NO:
2885;
and CDRL3 of SEQ ID NO:
3579;
or
(xxix) CDRH1 of SEQ ID NO:
106;
CDRH2 of SEQ ID NO:
802;
CDRH3 of SEQ ID NO:
1498;
CDRL1 of SEQ ID NO:
2192;
CDRL2 of SEQ ID NO:
2886;
and CDRL3 of SEQ ID NO:
3580;
or
(xxx) CDRH1 of SEQ ID NO:
107;
CDRH2 of SEQ ID NO:
803;
CDRH3 of SEQ ID NO:
1499;
CDRL1 of SEQ ID NO:
2193;
CDRL2 of SEQ ID NO:
2887;
and CDRL3 of SEQ ID NO:
3581;
or
(xxxi) CDRH1 of SEQ ID NO:
108;
CDRH2 of SEQ ID NO:
804;
CDRH3 of SEQ ID NO:
1500;
CDRL1 of SEQ ID NO:
2194;
CDRL2 of SEQ ID NO:
2888;
CDRL3 of SEQ ID NO:
3582;
or
(xxxii) CDRH1 of SEQ ID NO:
109;
CDRH2 of SEQ ID NO:
805;
CDRH3 of SEQ ID NO:
1501;
CDRL1 of SEQ ID NO:
2195;
CDRL2 of SEQ ID NO:
2889;
and CDRL3 of SEQ ID NO:
3583;
or
(xxxiii) CDRH1 of SEQ ID NO:
110;
CDRH2 of SEQ ID NO:
806;
CDRH3 of SEQ ID NO:
1502;
CDRL1 of SEQ ID NO:
2196;
CDRL2 of SEQ ID NO:2890;
and CDRL3 of SEQ ID NO:
3584;
or
(xxxiv) CDRH1 of SEQ ID NO:
111;
CDRH2 of SEQ ID NO:
807;
CDRH3 of SEQ ID NO:
1503;
CDRL1 of SEQ ID NO:
2197;
CDRL2 of SEQ ID NO:2891;
and CDRL3 of SEQ ID NO:
3585;
or
(xxxv) CDRH1 of SEQ ID NO:
112;
CDRH2 of SEQ ID NO:
808;
CDRH3 of SEQ ID NO:
1504;
CDRL1 of SEQ ID NO:
2198;
CDRL2 of SEQ ID NO:
2892;
and CDRL3 of SEQ ID NO:
3586;
or
(xxxvi) CDRH1 of SEQ ID NO:
113;
CDRH2 of SEQ ID NO:
809;
CDRH3 of SEQ ID NO:
1505;
CDRL1 of SEQ ID NO:
2199;
CDRL2 of SEQ ID NO:
2893;
and CDRL3 of SEQ ID NO:
3587;
or
(xxxvii) CDRH1 of SEQ ID NO:
114;
CDRH2 of SEQ ID NO:
810;
CDRH3 of SEQ ID NO:
1506;
CDRL1 of SEQ ID NO:
2200;
CDRL2 of SEQ ID NO:
2894;
CDRL3 of SEQ ID NO:
3588;
or
(xxxviii) CDRH1 of SEQ ID NO:
115;
CDRH2 of SEQ ID NO:
811;
CDRH3 of SEQ ID NO:
1507;
CDRL1 of SEQ ID NO:
2201;
CDRL2 of SEQ ID NO:
2895;
and CDRL3 of SEQ ID NO:
3589;
or
(xxxix) CDRH1 of SEQ ID NO:
116;
CDRH2 of SEQ ID NO:
812;
CDRH3 of SEQ ID NO:
1508;
CDRL1 of SEQ ID NO:
2202;
CDRL2 of SEQ ID NO:
2896;
and CDRL3 of SEQ ID NO:
3590;
or
(xl) CDRH1 of SEQ ID NO:
117;
CDRH2 of SEQ ID NO:
813;
CDRH3 of SEQ ID NO:
1509;
CDRL1 of SEQ ID NO:
2203;
CDRL2 of SEQ ID NO:
2897;
and CDRL3 of SEQ ID NO:
3591;
or
(xli) CDRH1 of SEQ ID NO:
118;
CDRH2 of SEQ ID NO:
814;
CDRH3 of SEQ ID NO:
1510;
CDRL1 of SEQ ID NO:
2204;
CDRL2 of SEQ ID NO:
2898;
and CDRL3 of SEQ ID NO:
3592;
or
(xlii) CDRH1 of SEQ ID NO:
119;
CDRH2 of SEQ ID NO:
815;
CDRH3 of SEQ ID NO:
1511;
CDRL1 of SEQ ID NO:
2205;
CDRL2 of SEQ ID NO:
2899;
and CDRL3 of SEQ ID NO:
3593.

540 more elements

Dependencies are inferred from the claim text.

Facts

Application: 19/563,667Filed 11 Mar 2026
Priority: 2 Jul 2019
Published: 24 Sep 2026
Term ends: Not estimatedThe source records don’t support an estimate.

Classification16 codes

C07K 16/2863
Against receptors, cell surface antigens or cell surface determinants: against receptors for growth factors, growth regulators
C07K 16/28
Against material from animals or humans: against receptors, cell surface antigens or cell surface determinants
A61K 38/00
Medicinal preparations containing peptides
C07K 2299/00
Coordinates from 3d structures of peptides

Family

Application62/869,976Us provisional application · filed 2 Jul 2019
Application62/875,073Us provisional application · filed 17 Jul 2019
Application17/623,006Continuation · filed 2 Jul 2020
Application19/563,667Continuation
US 12,606,629 B2Related patent
US 2022/0275095 A1Published application
US 2026/0285987 A1This patent

From the US filing history. Foreign family members aren’t listed.

Timeline

Citations

Open elsewhere

Building an agent or pulling many patents? Use the API or MCP server instead of scraping pages. Get an API key

patentgrep

Loading patent…

Abstract

The present invention provides anti-Fzd monoclonal antibodies and related compositions, which may be used in any of a variety of therapeutic methods for the treatment of diseases.

An isolated antibody, or an antigen-binding fragment thereof, that binds to a Frizzled 2 (FZD2) receptor, comprising CDR sequences comprising:

(i) CDRH1 of SEQ ID NO:
75;
CDRH2 of SEQ ID NO:
771;
CDRH3 of SEQ ID NO:
1467;
CDRL1 of SEQ ID NO:
2163;
CDRL2 of SEQ ID NO:
2857;
and CDRL3 of SEQ ID NO:
3551;
or
(ii) CDRH1 of SEQ ID NO:
76;
CDRH2 of SEQ ID NO:
772;
CDRH3 of SEQ ID NO:
1468;
CDRL1 of SEQ ID NO:
2164;
CDRL2 of SEQ ID NO:
2858;
and CDRL3 of SEQ ID NO:
3552;
or
(iii) CDRH1 of SEQ ID NO:
77;
CDRH2 of SEQ ID NO:
773;
CDRH3 of SEQ ID NO:
1469;
CDRL1 of SEQ ID NO:
2165;
CDRL2 of SEQ ID NO:
2859;
and CDRL3 of SEQ ID NO:
3553;
or
(iv) CDRH1 of SEQ ID NO:
78;
CDRH2 of SEQ ID NO:
774;
CDRH3 of SEQ ID NO:
1470;
CDRL1 of SEQ ID NO:
2166;
CDRL2 of SEQ ID NO:
2860;
and CDRL3 of SEQ ID NO:
3554;
or
(v) CDRH1 of SEQ ID NO:
79;
CDRH2 of SEQ ID NO:
775;
CDRH3 of SEQ ID NO:
1471;
CDRL1 of SEQ ID NO:
2167;
CDRL2 of SEQ ID NO:
2861;
and CDRL3 of SEQ ID NO:
3555;
or
(vi) CDRH1 of SEQ ID NO:
80;
CDRH2 of SEQ ID NO:
776;
CDRH3 of SEQ ID NO:
1472;
CDRL1 of SEQ ID NO:
2168;
CDRL2 of SEQ ID NO:
2862;
and CDRL3 of SEQ ID NO:
3556;
or
(vii) CDRH1 of SEQ ID NO:
81;
CDRH2 of SEQ ID NO:
777;
CDRH3 of SEQ ID NO:
1473;
CDRL1 of SEQ ID NO:
2169;
CDRL2 of SEQ ID NO:
2863;
and CDRL3 of SEQ ID NO:
3557;
or
(viii) CDRH1 of SEQ ID NO:
82;
CDRH2 of SEQ ID NO:
778;
CDRH3 of SEQ ID NO:
1474;
CDRL1 of SEQ ID NO:
2170;
CDRL2 of SEQ ID NO:
2864;
and CDRL3 of SEQ ID NO:
3558;
or
(ix) CDRH1 of SEQ ID NO:
83;
CDRH2 of SEQ ID NO:
779;
CDRH3 of SEQ ID NO:
1475;
CDRL1 of SEQ ID NO:
2171;
CDRL2 of SEQ ID NO:
2865;
and CDRL3 of SEQ ID NO:
3559;
or
(x) CDRH1 of SEQ ID NO:
84;
CDRH2 of SEQ ID NO:
780;
CDRH3 of SEQ ID NO:
1476;
CDRL1 of SEQ ID NO:
2172;
CDRL2 of SEQ ID NO:
2866;
and CDRL3 of SEQ ID NO:
3560;
or
(xi) CDRH1 of SEQ ID NO:
85;
CDRH2 of SEQ ID NO:
781;
CDRH3 of SEQ ID NO:
1477;
CDRL1 of SEQ ID NO:
2173;
CDRL2 of SEQ ID NO:
2867;
and CDRL3 of SEQ ID NO:
3561;
or
(xii) CDRH1 of SEQ ID NO:
86;
CDRH2 of SEQ ID NO:
782;
CDRH3 of SEQ ID NO:
1478;
CDRL1 of SEQ ID NO:
2174;
CDRL2 of SEQ ID NO:
2868;
and CDRL3 of SEQ ID NO:
3562;
or
(xiii) CDRH1 of SEQ ID NO:
87;
CDRH2 of SEQ ID NO:
783;
CDRH3 of SEQ ID NO:
1479;
CDRL1 of SEQ ID NO:
2175;
CDRL2 of SEQ ID NO:
2869;
and CDRL3 of SEQ ID NO:
3563;
or
(xiv) CDRH1 of SEQ ID NO:
88;
CDRH2 of SEQ ID NO:
784;
CDRH3 of SEQ ID NO:
1480;
CDRL1 of SEQ ID NO:
2176;
CDRL2 of SEQ ID NO:
2870;
and CDRL3 of SEQ ID NO:
3564;
or
(xv) CDRH1 of SEQ ID NO:
89;
CDRH2 of SEQ ID NO:
785;
CDRH3 of SEQ ID NO:
1481;
CDRL1 of SEQ ID NO:
2177;
CDRL2 of SEQ ID NO:
2871;
and CDRL3 of SEQ ID NO:
3565;
or
(xvi) CDRH1 of SEQ ID NO:
90;
CDRH2 of SEQ ID NO:
786;
CDRH3 of SEQ ID NO:
1482;
CDRL1 of SEQ ID NO:
2178;
CDRL2 of SEQ ID NO:
2872;
and CDRL3 of SEQ ID NO:
3566;
or
(xvii) CDRH1 of SEQ ID NO:
91;
CDRH2 of SEQ ID NO:
787;
CDRH3 of SEQ ID NO:
1483;
CDRL1 of SEQ ID NO:
2179;
CDRL2 of SEQ ID NO:
2873;
and CDRL3 of SEQ ID NO:
3567;
or
(xviii) CDRH1 of SEQ ID NO:
92;
CDRH2 of SEQ ID NO:
788;
CDRH3 of SEQ ID NO:
1484;
CDRL1 of SEQ ID NO:
2180;
CDRL2 of SEQ ID NO:
2874;
and CDRL3 of SEQ ID NO:
3568;
or
(xix) CDRH1 of SEQ ID NO:
94;
CDRH2 of SEQ ID NO:
790;
CDRH3 of SEQ ID NO:
1486;
CDRL1 of SEQ ID NO:
2181;
CDRL2 of SEQ ID NO:
2875;
CDRL3 of SEQ ID NO:
3569;
or
(xx) CDRH1 of SEQ ID NO:
95;
CDRH2 of SEQ ID NO:
791;
CDRH3 of SEQ ID NO:
1487;
CDRL1 of SEQ ID NO:
2182;
CDRL2 of SEQ ID NO:
2876;
and CDRL3 of SEQ ID NO:
3570;
or
(xxi) CDRH1 of SEQ ID NO:
97;
CDRH2 of SEQ ID NO:
793;
CDRH3 of SEQ ID NO:
1489;
CDRL1 of SEQ ID NO:
2184;
CDRL2 of SEQ ID NO:
2878;
and CDRL3 of SEQ ID NO:
3572;
or
(xxii) CDRH1 of SEQ ID NO:
98;
CDRH2 of SEQ ID NO:
794;
CDRH3 of SEQ ID NO:
1490;
CDRL1 of SEQ ID NO:
2185;
CDRL2 of SEQ ID NO:
2879;
and CDRL3 of SEQ ID NO:
3573;
or
(xxiii) CDRH1 of SEQ ID NO:
99;
CDRH2 of SEQ ID NO:
795;
CDRH3 of SEQ ID NO:
1491;
CDRL1 of SEQ ID NO:
2186;
CDRL2 of SEQ ID NO:
2880;
and CDRL3 of SEQ ID NO:
3574;
or
(xxiv) CDRH1 of SEQ ID NO:
100;
CDRH2 of SEQ ID NO:
796;
CDRH3 of SEQ ID NO:
1492;
CDRL1 of SEQ ID NO:
2187;
CDRL2 of SEQ ID NO:
2881;
and CDRL3 of SEQ ID NO:
3575;
or
(xxv) CDRH1 of SEQ ID NO:
101;
CDRH2 of SEQ ID NO:
797;
CDRH3 of SEQ ID NO:
1493;
CDRL1 of SEQ ID NO:
2188;
CDRL2 of SEQ ID NO:
2882;
and CDRL3 of SEQ ID NO:
3576;
or
(xxvi) CDRH1 of SEQ ID NO:
103;
CDRH2 of SEQ ID NO:
799;
CDRH3 of SEQ ID NO:
1495;
CDRL1 of SEQ ID NO:
2189;
CDRL2 of SEQ ID NO:
2883;
and CDRL3 of SEQ ID NO:
3577;
or
(xxvii) CDRH1 of SEQ ID NO:
104;
CDRH2 of SEQ ID NO:
800;
CDRH3 of SEQ ID NO:
1496;
CDRL1 of SEQ ID NO:
2190;
CDRL2 of SEQ ID NO:
2884;
and CDRL3 of SEQ ID NO:
3578;
or
(xxviii) CDRH1 of SEQ ID NO:
105;
CDRH2 of SEQ ID NO:
801;
CDRH3 of SEQ ID NO:
1497;
CDRL1 of SEQ ID NO:
2191;
CDRL2 of SEQ ID NO:
2885;
and CDRL3 of SEQ ID NO:
3579;
or
(xxix) CDRH1 of SEQ ID NO:
106;
CDRH2 of SEQ ID NO:
802;
CDRH3 of SEQ ID NO:
1498;
CDRL1 of SEQ ID NO:
2192;
CDRL2 of SEQ ID NO:
2886;
and CDRL3 of SEQ ID NO:
3580;
or
(xxx) CDRH1 of SEQ ID NO:
107;
CDRH2 of SEQ ID NO:
803;
CDRH3 of SEQ ID NO:
1499;
CDRL1 of SEQ ID NO:
2193;
CDRL2 of SEQ ID NO:
2887;
and CDRL3 of SEQ ID NO:
3581;
or
(xxxi) CDRH1 of SEQ ID NO:
108;
CDRH2 of SEQ ID NO:
804;
CDRH3 of SEQ ID NO:
1500;
CDRL1 of SEQ ID NO:
2194;
CDRL2 of SEQ ID NO:
2888;
CDRL3 of SEQ ID NO:
3582;
or
(xxxii) CDRH1 of SEQ ID NO:
109;
CDRH2 of SEQ ID NO:
805;
CDRH3 of SEQ ID NO:
1501;
CDRL1 of SEQ ID NO:
2195;
CDRL2 of SEQ ID NO:
2889;
and CDRL3 of SEQ ID NO:
3583;
or
(xxxiii) CDRH1 of SEQ ID NO:
110;
CDRH2 of SEQ ID NO:
806;
CDRH3 of SEQ ID NO:
1502;
CDRL1 of SEQ ID NO:
2196;
CDRL2 of SEQ ID NO:2890;
and CDRL3 of SEQ ID NO:
3584;
or
(xxxiv) CDRH1 of SEQ ID NO:
111;
CDRH2 of SEQ ID NO:
807;
CDRH3 of SEQ ID NO:
1503;
CDRL1 of SEQ ID NO:
2197;
CDRL2 of SEQ ID NO:2891;
and CDRL3 of SEQ ID NO:
3585;
or
(xxxv) CDRH1 of SEQ ID NO:
112;
CDRH2 of SEQ ID NO:
808;
CDRH3 of SEQ ID NO:
1504;
CDRL1 of SEQ ID NO:
2198;
CDRL2 of SEQ ID NO:
2892;
and CDRL3 of SEQ ID NO:
3586;
or
(xxxvi) CDRH1 of SEQ ID NO:
113;
CDRH2 of SEQ ID NO:
809;
CDRH3 of SEQ ID NO:
1505;
CDRL1 of SEQ ID NO:
2199;
CDRL2 of SEQ ID NO:
2893;
and CDRL3 of SEQ ID NO:
3587;
or
(xxxvii) CDRH1 of SEQ ID NO:
114;
CDRH2 of SEQ ID NO:
810;
CDRH3 of SEQ ID NO:
1506;
CDRL1 of SEQ ID NO:
2200;
CDRL2 of SEQ ID NO:
2894;
CDRL3 of SEQ ID NO:
3588;
or
(xxxviii) CDRH1 of SEQ ID NO:
115;
CDRH2 of SEQ ID NO:
811;
CDRH3 of SEQ ID NO:
1507;
CDRL1 of SEQ ID NO:
2201;
CDRL2 of SEQ ID NO:
2895;
and CDRL3 of SEQ ID NO:
3589;
or
(xxxix) CDRH1 of SEQ ID NO:
116;
CDRH2 of SEQ ID NO:
812;
CDRH3 of SEQ ID NO:
1508;
CDRL1 of SEQ ID NO:
2202;
CDRL2 of SEQ ID NO:
2896;
and CDRL3 of SEQ ID NO:
3590;
or
(xl) CDRH1 of SEQ ID NO:
117;
CDRH2 of SEQ ID NO:
813;
CDRH3 of SEQ ID NO:
1509;
CDRL1 of SEQ ID NO:
2203;
CDRL2 of SEQ ID NO:
2897;
and CDRL3 of SEQ ID NO:
3591;
or
(xli) CDRH1 of SEQ ID NO:
118;
CDRH2 of SEQ ID NO:
814;
CDRH3 of SEQ ID NO:
1510;
CDRL1 of SEQ ID NO:
2204;
CDRL2 of SEQ ID NO:
2898;
and CDRL3 of SEQ ID NO:
3592;
or
(xlii) CDRH1 of SEQ ID NO:
119;
CDRH2 of SEQ ID NO:
815;
CDRH3 of SEQ ID NO:
1511;
CDRL1 of SEQ ID NO:
2205;
CDRL2 of SEQ ID NO:
2899;
and CDRL3 of SEQ ID NO:
3593.

540 more elements

Facts

Application

19/563,667Filed 11 Mar 2026

Priority

2 Jul 2019

Published

24 Sep 2026

Term ends

Not estimatedThe source records don’t support an estimate.

Classification16 codes

C07K 16/2863
Against receptors, cell surface antigens or cell surface determinants: against receptors for growth factors, growth regulators
C07K 16/28
Against material from animals or humans: against receptors, cell surface antigens or cell surface determinants
A61K 38/00
Medicinal preparations containing peptides
C07K 2299/00
Coordinates from 3d structures of peptides

Family

Application62/869,976Us provisional application · filed 2 Jul 2019

Application62/875,073Us provisional application · filed 17 Jul 2019

Application17/623,006Continuation · filed 2 Jul 2020

Application19/563,667Continuation

US 12,606,629 B2Related patent

US 2022/0275095 A1Published application

US 2026/0285987 A1This patent

From the US filing history. Foreign family members aren’t listed.